Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia.

Al-Sawaf O, Herling CD, Holtick U, Scheid C, Cramer P, Sasse S, von Tresckow B, Tuchscherer A, Fischer K, Eichhorst B, Hallek M, Frenzel LP.

Haematologica. 2019 May;104(5):e224-e226. doi: 10.3324/haematol.2018.212837. Epub 2019 Feb 21. No abstract available.

2.

Sequential therapy for patients with primary refractory acute myeloid leukemia - historical prospective analysis of the German and Israeli experience.

Ram R, Scheid C, Amit O, Chemnitz JM, Moshe Y, Hallek M, Wolf D, Avivi I, Holtick U.

Haematologica. 2019 Feb 7. pii: haematol.2018.203869. doi: 10.3324/haematol.2018.203869. [Epub ahead of print]

3.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Apr 10;24(4):526. doi: 10.1038/nm0418-526c.

PMID:
29634689
4.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12. Erratum in: Nat Med. 2018 Apr 10;24(4):526.

5.

Impact of choice, timing, sequence and combination of broad-spectrum antibiotics on the outcome of allogeneic haematopoietic stem cell transplantation.

Farowski F, Bücker V, Vehreschild JJ, Biehl L, Cruz-Aguilar R, Scheid C, Holtick U, Jazmati N, Wisplinghoff H, Cornely OA, Vehreschild MJGT.

Bone Marrow Transplant. 2018 Jan;53(1):52-57. doi: 10.1038/bmt.2017.203. Epub 2017 Nov 13.

PMID:
29131156
6.

Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use.

Lock D, Mockel-Tenbrinck N, Drechsel K, Barth C, Mauer D, Schaser T, Kolbe C, Al Rawashdeh W, Brauner J, Hardt O, Pflug N, Holtick U, Borchmann P, Assenmacher M, Kaiser A.

Hum Gene Ther. 2017 Oct;28(10):914-925. doi: 10.1089/hum.2017.111.

PMID:
28847167
7.

Dynamics of Torque Teno virus viremia could predict risk of complications after allogeneic hematopoietic stem cell transplantation.

Gilles R, Herling M, Holtick U, Heger E, Awerkiew S, Fish I, Höller K, Sierra S, Knops E, Kaiser R, Scheid C, Di Cristanziano V.

Med Microbiol Immunol. 2017 Oct;206(5):355-362. doi: 10.1007/s00430-017-0511-4. Epub 2017 Jul 12.

PMID:
28702856
8.

Dynamics of BKPyV reactivation and risk of hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation.

Höller K, Fabeni L, Herling M, Holtick U, Scheid C, Knops E, Lübke N, Kaiser R, Pfister H, Di Cristanziano V.

Eur J Haematol. 2017 Aug;99(2):133-140. doi: 10.1111/ejh.12895. Epub 2017 May 30.

PMID:
28401591
9.

Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML.

Holtick U, Herling M, Pflug N, Chakupurakal G, Leitzke S, Wolf D, Hallek M, Scheid C, Chemnitz JM.

Ann Hematol. 2017 Mar;96(3):479-487. doi: 10.1007/s00277-016-2887-4. Epub 2016 Dec 1.

PMID:
27909887
10.

Impact of genomic risk factors on survival after haematopoietic stem cell transplantation for patients with acute leukaemia.

Pearce KF, Balavarca Y, Norden J, Jackson G, Holler E, Dressel R, Greinix H, Toubert A, Gluckman E, Hromadnikova I, Sedlacek P, Wolff D, Holtick U, Bickeböller H, Dickinson AM.

Int J Immunogenet. 2016 Dec;43(6):404-412. doi: 10.1111/iji.12295. Epub 2016 Nov 9.

PMID:
27870355
11.

Corneal Densitometry for Quantification of Corneal Deposits in Monoclonal Gammopathies.

Enders P, Holtick U, Schaub F, Tuchscherer A, Hermann MM, Scheid C, Cursiefen C, Bachmann BO.

Cornea. 2017 Apr;36(4):470-475. doi: 10.1097/ICO.0000000000001078.

PMID:
27841786
12.

Regulatory B10 cells display an altered homoeostasis in acute graft-versus-host disease.

Chakupurakal G, Garcia-Marquez MA, Shimabukuro-Vornhagen A, Kluth S, Schlosser H, Theurich S, Scheid C, Hallek M, Holtick U, von Bergwelt-Baildon M.

Eur J Haematol. 2017 Feb;98(2):128-133. doi: 10.1111/ejh.12810. Epub 2016 Nov 6.

PMID:
27717015
13.

Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from a sealed manufacturing system: a retrospective cohort study.

Tahmaz V, Gehlsen U, Sauerbier L, Holtick U, Engel L, Radojska S, Petrescu-Jipa VM, Scheid C, Hallek M, Gathof B, Cursiefen C, Steven P.

Br J Ophthalmol. 2017 Mar;101(3):322-326. doi: 10.1136/bjophthalmol-2015-307666. Epub 2016 Jun 6.

PMID:
27267447
14.

Persistent CMV infection after allogeneic hematopoietic stem cell transplantation in a CMV-seronegative donor-to-positive recipient constellation: Development of multidrug resistance in the absence of anti-viral cellular immunity.

Herling M, Schröder L, Awerkiew S, Chakupurakal G, Holtick U, Kaiser R, Pfister H, Scheid C, Di Cristanziano V.

J Clin Virol. 2016 Jan;74:57-60. doi: 10.1016/j.jcv.2015.11.033. Epub 2015 Nov 30.

PMID:
26672492
15.

Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody.

Chakupurakal G, García-Márquez MA, Shimabukuro-Vornhagen A, Theurich S, Holtick U, Hallek M, Scheid C, von Bergwelt-Baildon M.

Eur J Haematol. 2016 Aug;97(2):121-7. doi: 10.1111/ejh.12691. Epub 2015 Nov 16.

PMID:
26492560
16.

Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality--a single institution experience.

Chakupurakal G, Leitzke S, Langerbeins P, Schiller J, Schneider PM, Holtick U, Shimabukuro-Vornhagen A, Theurich S, Chemnitz J, Hallek M, von Bergwelt-Baildon M, Scheid C.

Ann Hematol. 2015 Oct;94(10):1717-25. doi: 10.1007/s00277-015-2449-1. Epub 2015 Aug 12.

PMID:
26259502
17.

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N.

Leukemia. 2015 Oct;29(10):2062-8. doi: 10.1038/leu.2015.212. Epub 2015 Jul 31.

18.

Predicting survival using clinical risk scores and non-HLA immunogenetics.

Balavarca Y, Pearce K, Norden J, Collin M, Jackson G, Holler E, Dressel R, Kolb HJ, Greinix H, Socie G, Toubert A, Rocha V, Gluckman E, Hromadnikova I, Sedlacek P, Wolff D, Holtick U, Dickinson A, Bickeböller H.

Bone Marrow Transplant. 2015 Nov;50(11):1445-52. doi: 10.1038/bmt.2015.173. Epub 2015 Jul 27.

PMID:
26214138
19.

FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission.

Holtick U, Shimabukuro-Vornhagen A, Chakupurakal G, Theurich S, Leitzke S, Burst A, Hallek M, von Bergwelt-Baildon M, Scheid C, Chemnitz JM.

Eur J Haematol. 2016 May;96(5):475-82. doi: 10.1111/ejh.12615. Epub 2015 Aug 25.

PMID:
26132980
20.

[Allogeneic haematopoietic stem cell transplantation - an overview].

Holtick U, Chemnitz JM, Hallek M, Scheid C.

Klin Monbl Augenheilkd. 2015 May;232(5):641-6. doi: 10.1055/s-0035-1545939. Epub 2015 May 19. Review. German.

PMID:
25989032
21.

Meibography and meibomian gland measurements in ocular graft-versus-host disease.

Engel LA, Wittig S, Bock F, Sauerbier L, Scheid C, Holtick U, Chemnitz JM, Hallek M, Cursiefen C, Steven P.

Bone Marrow Transplant. 2015 Jul;50(7):961-7. doi: 10.1038/bmt.2015.72. Epub 2015 Apr 20.

PMID:
25893453
22.

OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation.

Holtick U, Chemnitz JM, Shimabukuro-Vornhagen A, Theurich S, Chakupurakal G, Krause A, Fiedler A, Luznik L, Hellmich M, Wolf D, Hallek M, von Bergwelt-Baildon M, Scheid C.

Eur J Haematol. 2016 Jan;96(1):27-35. doi: 10.1111/ejh.12541. Epub 2015 Mar 16.

23.

Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults - a systematic review and meta-analysis.

Holtick U, Albrecht M, Chemnitz JM, Theurich S, Shimabukuro-Vornhagen A, Skoetz N, Scheid C, von Bergwelt-Baildon M.

Crit Rev Oncol Hematol. 2015 May;94(2):179-88. doi: 10.1016/j.critrevonc.2014.12.007. Epub 2014 Dec 18. Review.

PMID:
25604498
24.

Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours.

Weihrauch MR, Richly H, von Bergwelt-Baildon MS, Becker HJ, Schmidt M, Hacker UT, Shimabukuro-Vornhagen A, Holtick U, Nokay B, Schroff M, Wittig B, Scheulen ME.

Eur J Cancer. 2015 Jan;51(2):146-56. doi: 10.1016/j.ejca.2014.11.002. Epub 2014 Dec 2.

PMID:
25480557
25.

Targeting Tumor-Infiltrating B Cells in Cutaneous T-Cell Lymphoma.

Theurich S, Schlaak M, Steguweit H, Heukamp LC, Wennhold K, Kurschat P, Rabenhorst A, Hartmann K, Schlösser H, Shimabukuro-Vornhagen A, Holtick U, Hallek M, Stadler R, von Bergwelt-Baildon M.

J Clin Oncol. 2016 Apr 20;34(12):e110-6. doi: 10.1200/JCO.2013.50.9471. Epub 2014 Oct 27. No abstract available.

PMID:
25348001
26.

Overcoming tumor-mediated immunosuppression.

Schlößer HA, Theurich S, Shimabukuro-Vornhagen A, Holtick U, Stippel DL, von Bergwelt-Baildon M.

Immunotherapy. 2014;6(9):973-88. doi: 10.2217/imt.14.58. Review.

PMID:
25341119
27.

[Hematopoietic stem cell transplantation: bone marrow and blood stem cells].

von Bergwelt-Baildon M, Holtick U, Hallek MJ, Scheid C.

Internist (Berl). 2014 Nov;55(11):1306-12. doi: 10.1007/s00108-014-3509-7. German.

PMID:
25323808
28.

Inhibition of protein geranylgeranylation specifically interferes with CD40-dependent B cell activation, resulting in a reduced capacity to induce T cell immunity.

Shimabukuro-Vornhagen A, Zoghi S, Liebig TM, Wennhold K, Chemitz J, Draube A, Kochanek M, Blaschke F, Pallasch C, Holtick U, Scheid C, Theurich S, Hallek M, von Bergwelt-Baildon MS.

J Immunol. 2014 Nov 15;193(10):5294-305. doi: 10.4049/jimmunol.1203436. Epub 2014 Oct 13.

29.

CD4+ T cell counts reflect the immunosuppressive state of CD4 helper cells in patients after allogeneic stem cell transplantation.

Holtick U, Frenzel LP, Shimabukuro-Vornhagen A, Theurich S, Claasen J, Scheid C, von Bergwelt-Baildon M, Fröhlich H, Wendtner CM, Chemnitz JM.

Ann Hematol. 2015 Jan;94(1):129-37. doi: 10.1007/s00277-014-2166-1. Epub 2014 Aug 15.

PMID:
25118994
30.

Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.

Holtick U, Albrecht M, Chemnitz JM, Theurich S, Skoetz N, Scheid C, von Bergwelt-Baildon M.

Cochrane Database Syst Rev. 2014 Apr 20;(4):CD010189. doi: 10.1002/14651858.CD010189.pub2. Review.

PMID:
24748537
31.

Pretransplant comorbidities maintain their impact on allogeneic stem cell transplantation outcome 5 years posttransplant: a retrospective study in a single german institution.

Chemnitz JM, Chakupurakal G, Bäßler M, Holtick U, Theurich S, Shimabukuro-Vornhagen A, Leitzke S, Von Bergwelt-Baildon MS, Scheid C.

ISRN Hematol. 2014 Mar 5;2014:853435. doi: 10.1155/2014/853435. eCollection 2014.

32.

CD30-targeted therapy with brentuximab vedotin and DLI in a patient with T-cell posttransplantation lymphoma: induction of clinical remission and cellular immunity.

Theurich S, Wennhold K, Wedemeyer I, Rothe A, Hübel K, Shimabukuro-Vornhagen A, Holtick U, Hallek M, Scheid C, von Bergwelt-Baildon M.

Transplantation. 2013 Aug 15;96(3):e16-8. doi: 10.1097/TP.0b013e31829a9258. No abstract available.

PMID:
23917689
33.

Anti-thymocyte globulins for post-transplant graft-versus-host disease prophylaxis-A systematic review and meta-analysis.

Theurich S, Fischmann H, Chakupurakal G, Shimabukuro-Vornhagen A, Chemnitz JM, Holtick U, Rothe A, Scheid C, Hallek M, Skoetz N, von Bergwelt-Baildon M.

Crit Rev Oncol Hematol. 2013 Oct;88(1):178-86. doi: 10.1016/j.critrevonc.2013.03.009. Epub 2013 Apr 2. Review.

PMID:
23561334
34.

Immature DC isolated after co-culture with PUVA-treated peripheral blood mononuclear cells downregulate graft-versus-host reactions in the human skin explant model.

Holtick U, Wang XN, Marshall SR, Scheid C, von Bergwelt-Baildon M, Dickinson AM.

Curr Stem Cell Res Ther. 2013 Jul;8(4):324-32.

PMID:
23363467
35.

Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission.

Theurich S, Malcher J, Wennhold K, Shimabukuro-Vornhagen A, Chemnitz J, Holtick U, Krause A, Kobe C, Kahraman D, Engert A, Scheid C, Chakupurakal G, Hallek M, von Bergwelt-Baildon M.

J Clin Oncol. 2013 Feb 10;31(5):e59-63. doi: 10.1200/JCO.2012.43.6832. Epub 2012 Dec 26. No abstract available.

PMID:
23269992
36.

Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.

Theurich S, Fischmann H, Shimabukuro-Vornhagen A, Chemnitz JM, Holtick U, Scheid C, Skoetz N, von Bergwelt-Baildon M.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009159. doi: 10.1002/14651858.CD009159.pub2. Review.

PMID:
22972135
37.

In vitro PUVA treatment preferentially induces apoptosis in alloactivated T cells.

Holtick U, Wang XN, Marshall SR, Scheid C, von Bergwelt-Baildon M, Dickinson AM.

Transplantation. 2012 Sep 15;94(5):e31-4. doi: 10.1097/TP.0b013e31825f4454. No abstract available.

PMID:
22955171
38.

Analysis of Tie2-expressing monocytes (TEM) in patients with colorectal cancer.

Goede V, Coutelle O, Shimabukuro-Vornhagen A, Holtick U, Neuneier J, Koslowsky TC, Weihrauch MR, von Bergwelt-Baildon M, Hacker UT.

Cancer Invest. 2012 Mar;30(3):225-30. doi: 10.3109/07357907.2011.636114. Epub 2011 Dec 15.

PMID:
22171993
39.

Reduced-intensity conditioning in allogeneic stem cell transplantation for hematological malignancies: a historical perspective.

Cremer B, Sandmaier BM, Bethge W, Lange T, Goede V, Holtick U, Hallek M, Hübel K.

Onkologie. 2011;34(12):710-5. doi: 10.1159/000334542. Epub 2011 Nov 23.

PMID:
22156452
40.

Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia.

Chemnitz JM, von Lilienfeld-Toal M, Holtick U, Theurich S, Shimabukuro-Vornhagen A, Krause A, Brossart P, Hallek M, Scheid C.

Ann Hematol. 2012 Jan;91(1):47-55. doi: 10.1007/s00277-011-1253-9. Epub 2011 May 17.

PMID:
21584670
41.

Targeting malignant B cells as antigen-presenting cells: TLR-9 agonist induces systemic regression of lymphoma.

Klein-González N, Holtick U, Fairfax K, Weihrauch MR, von Bergwelt-Baildon MS.

Expert Rev Vaccines. 2011 Mar;10(3):295-8. doi: 10.1586/erv.11.6.

PMID:
21434797
42.

Potential of Toll-like receptor 9 agonists in combined anticancer immunotherapy strategies: synergy of PAMPs and DAMPs?

Holtick U, Klein-Gonzalez N, von Bergwelt-Baildon MS.

Immunotherapy. 2011 Mar;3(3):301-4. doi: 10.2217/imt.10.118. No abstract available.

43.

Haploidentical bone marrow transplantation with post-grafting cyclophosphamide: multicenter experience with an alternative salvage strategy.

Tuve S, Gayoso J, Scheid C, Radke J, Kiani A, Serrano D, Platzbecker U, Rodríguez-Macías G, Wermke M, Holtick U, Balsalobre P, Middeke JM, Shayegi N, Chemnitz JM, Krause A, Gruner N, Füssel M, Schetelig J, Thiede C, Ehninger G, Hallek M, Díez-Martín JL, Bornhäuser M.

Leukemia. 2011 May;25(5):880-3. doi: 10.1038/leu.2011.11. Epub 2011 Feb 11. No abstract available.

PMID:
21311556
44.

Toll-like receptor 9 agonists as cancer therapeutics.

Holtick U, Scheulen ME, von Bergwelt-Baildon MS, Weihrauch MR.

Expert Opin Investig Drugs. 2011 Mar;20(3):361-72. doi: 10.1517/13543784.2011.553187. Epub 2011 Jan 22. Review.

PMID:
21254877
45.

Regulatory T-cell suppression of CD8+ T-cell-mediated graft-versus-host reaction requires their presence during priming.

Wang XN, Haniffa MA, Holtick U, Collin MP, Jackson G, Hilkens CM, Holler E, Edinger M, Hoffmann P, Dickinson AM.

Transplantation. 2009 Jul 27;88(2):188-97. doi: 10.1097/TP.0b013e3181ac14ce.

PMID:
19623013
46.

Post-transplant immunotherapy: combining cancer vaccines with hematopoietic stem cell transplantation.

Holtick U, von Bergwelt-Baildon M.

Expert Rev Vaccines. 2009 May;8(5):519-23. doi: 10.1586/erv.09.24. No abstract available.

PMID:
19397408
47.

Impact of psoralen/UVA-treatment on survival, activation, and immunostimulatory capacity of monocyte-derived dendritic cells.

Holtick U, Marshall SR, Wang XN, Hilkens CM, Dickinson AM.

Transplantation. 2008 Mar 15;85(5):757-66. doi: 10.1097/TP.0b013e31816650f6.

PMID:
18337671
48.

U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease.

Scarisbrick JJ, Taylor P, Holtick U, Makar Y, Douglas K, Berlin G, Juvonen E, Marshall S; Photopheresis Expert Group.

Br J Dermatol. 2008 Apr;158(4):659-78. doi: 10.1111/j.1365-2133.2007.08415.x. Epub 2008 Jan 30.

PMID:
18241274
49.

Potent graft-versus-leukemia effect in BCR/ABL negative chronic myelogenous leukemia.

Holtick U, Marshall SR, O'Brien SG, Collin MP.

Blood. 2007 Dec 15;110(13):4622-3. No abstract available.

50.

Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells.

Haniffa MA, Wang XN, Holtick U, Rae M, Isaacs JD, Dickinson AM, Hilkens CM, Collin MP.

J Immunol. 2007 Aug 1;179(3):1595-604.

Supplemental Content

Loading ...
Support Center